CEO, Tanya Collin-Histed writes; The IGA works closely alongside the pharmaceutical companies that have charitable access programmes to ensure no-one gets left behind.
Earlier this year several Gaucher patients applied for charitable treatment through Takeda’s Charitable Access programme; four cases were approved and those that were not, as the number of applications exceeded the amount of ERT available, the IGA sent through to Sanofi Genzyme for their consideration.
Sudan is currently facing some very challenging times and getting treatment into the country is difficult. However, working with Sanofi Genzyme and Mr Mohammed Bashir (the father of a Gaucher patient originally from Sudan) enabled the remaining three applications to be completed and we are delighted that these children have been approved.
#togetherwearestronger #drivenbypassionforpatients #patientvoice #advocacy #charitableaid #humanitarianaid